About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Pathology
›
top-articles
Department of Pathology
73
(top 1%)
papers
11.9K
(top 1%)
citations
40
(top 1%)
h
-index
69
(top 1%)
g
-index
74
all documents
12.3K
doc citations
2.3K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
Cell
1997
4,620
2
The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development
Cell
2000
674
3
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Science
2006
652
4
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
Journal of Cell Biology
1999
634
5
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
Nature
2000
623
6
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Nature
2010
510
7
Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease
Nature Genetics
2001
451
8
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Nature Medicine
2016
224
9
Embryonic cardiomyocyte hypoplasia and craniofacial defects in Galpha q/Galpha 11-mutant mice
EMBO Journal
1998
216
10
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis
Clinical and Experimental Metastasis
2008
193
11
Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue
Cell Metabolism
2015
172
12
Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
Clinical Colorectal Cancer
2008
147
13
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
Cancer Cell
2014
137
14
Macroscopic cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells
Journal of Cell Science
2003
136
15
Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to Pain
PLoS ONE
2014
135
16
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
Journal of Biological Chemistry
2008
131
17
SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia
Oncogene
2003
130
18
FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice
PLoS ONE
2012
127
19
Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy
Trends in Molecular Medicine
1996
117
20
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
Journal of Cellular Biochemistry
1999
116
21
Systemically and Topically Administered Leptin Both Accelerate Wound Healing in Diabetic ob/ob Mice
Endocrinology
2000
115
22
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Molecular Cancer Therapeutics
2015
112
23
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
Cancer Research
2000
109
24
Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury
Journal of Bone and Mineral Research
2011
106
25
The effects of keratinocyte growth factor in preclinical models of mucositis
Cell Proliferation
2002
100
26
Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice
International Journal of Radiation Biology
1999
95
27
RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis
Journal of Bone and Mineral Research
2005
94
28
Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy
Journal of Biomedicine and Biotechnology
2011
92
29
Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors
1999
91
30
Myofibroblast and α1(III) collagen expression in experimental tubulointerstitial nephritis
Kidney International
1997
78
31
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies
Arthritis Research and Therapy
2009
75
32
Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries
Veterinary Clinical Pathology
2013
62
33
RANK expression as a prognostic and predictive marker in breast cancer
Breast Cancer Research and Treatment
2014
59
34
Chemokine expression in experimental tubulointerstitial nephritis.
Journal of Immunology
1997
58
35
The Stress Kinase Mitogen-Activated Protein Kinase Kinase (Mkk)7 Is a Negative Regulator of Antigen Receptor and Growth Factor Receptor–Induced Proliferation in Hematopoietic Cells
Journal of Experimental Medicine
2001
56
36
Deregulation of Cyclin E2 expression and associated kinase activity in primary breast tumors
Oncogene
2002
49
37
A comparability study of 5 commercial KRAS tests
Diagnostic Pathology
2010
47
38
RANK and RANK ligand expression in primary human osteosarcoma
Journal of Bone Oncology
2015
47
39
Chemokine expression in experimental tubulointerstitial nephritis
Journal of Immunology
1997
47
40
Trefoil peptide expression and goblet cell number in rat intestine: effects of KGF and fasting-refeeding
American Journal of Physiology - Regulatory Integrative and Comparative Physiology
2003
44
41
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
British Journal of Cancer
2011
42
42
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
Bone
2010
40
43
Isoflurane leakage from non-rebreathing rodent anaesthesia circuits: comparison of emissions from conventional and modified ports
Laboratory Animals
2006
39
44
The Candidate Neuroprotective Agent Artemin Induces Autonomic Neural Dysplasia without Preventing Peripheral Nerve Dysfunction
Toxicologic Pathology
2004
38
45
Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis
Diabetes, Obesity and Metabolism
2009
34
46
The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice
Immunology
2003
33
47
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model
Breast Cancer Research and Treatment
2012
33
48
Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
Apoptosis: an International Journal on Programmed Cell Death
2007
31
49
Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts
International Journal of Cancer
2003
28
50
Peroxisome Proliferators and Receptor-Mediated Hepatic Carcinogenesis
Toxicologic Pathology
2004
28
site/software ©
exaly
; All materials licenced under
CC by-SA
.